Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMJ0A2R)

• Drug Name: IU1 Drug Info
• Synonyms: 314245-33-5; 1-[1-(4-Fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(1-pyrrolidinyl)ethanone; 1-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(pyrrolidin-1-yl)ethan-1-one; IU-1; 1-[1-(4-fluorophenyl)-2,5-dimethylpyrrol-3-yl]-2-pyrrolidin-1-ylethanone; 1-(1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)-2-(pyrrolidin-1-yl)ethanone; CHEMBL1410015; MFCD01917473; 1-(1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)-2-(pyrrolidin-1-yl)ethan-1-one; 1-[1-(4-Fluoro-phenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-pyrrolidin-1-yl-ethanone; Usp14 inhibitor; MLS001032847; GTPL8880; SCHEMBL6923146; ZINC38235; DTXSID80350196; HMS1726C11; HMS2742M13; HMS3653I09; HMS3743A07; AMY24153; BCP12722; EX-A2079; 2486AH; BDBM50437694; s7134; AKOS000811299; IU1, >=98% (HPLC); CCG-190730; CS-7546; MCULE-9620933012; NE48827; QC-8208; SB19054; NCGC00249377-01; NCGC00249377-04; NCGC00249377-08; AC-32694; DA-33458; HY-13817; SMR000363441; ST054127; AB0097167; FT-0716455; MLS001032847-02; SW219677-1; EN300-72884; SR-01000010584; J-018415; SR-01000010584-1; Z55133506; F1142-1244; 1-[1-(4-fluorophenyl)-2,5-dimethylpyrrol-3-yl]-2-pyrrolidinylethan-1-one; 1-[1-(4-FLUOROPHENYL)-2,5-DIMETHYLPYRROL-3-YL]-2-(PYRROLIDIN-1-YL)ETHANONE
• Cross-matching ID:
  PubChem CID: 675434
  ChEBI ID: CHEMBL1410015
  CAS Number: CAS 314245-33-5
  TTD Drug ID: DW0Z1Y

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Hematopoietic cell lineage	-1.68	4.52e-2	90/99 (90.91%)	ITGA6;MME;CD59;...
Primary immunodeficiency	-1.69	4.42e-2	33/38 (86.84%)	IL2RG;DCLRE1C;IGLL1;...
Graft-versus-host disease	-1.69	4.08e-2	32/42 (76.19%)	KIR2DL3;GZMB;KLRD1;...
Acute myeloid leukemia	-1.70	4.05e-2	66/67 (98.51%)	RUNX1;GRB2;RPS6KB2;...
Arginine biosynthesis	-1.71	4.02e-2	17/22 (77.27%)	GLS;CPS1;GLUD1;...
FoxO signaling pathway	-1.75	2.95e-2	118/131 (90.08%)	ARAF;SOD2;FOXO4;...
Porphyrin and chlorophyll metabolism	-1.77	2.62e-2	23/43 (53.49%)	HMOX2;ALAS2;PPOX;...
Fatty acid degradation	-1.82	2.21e-2	40/43 (93.02%)	GCDH;ALDH9A1;ALDH7A1;...
Inflammatory bowel disease	-1.84	2.31e-2	58/65 (89.23%)	HLA-DQB1;IFNGR2;STAT4;...
Pyruvate metabolism	-1.86	1.96e-2	41/47 (87.23%)	ME1;ME2;PC;...
JAK-STAT signaling pathway	-1.88	1.47e-2	146/162 (90.12%)	IL24;GRB2;SOCS2;...
Steroid biosynthesis	-1.89	1.84e-2	19/20 (95%)	SQLE;SOAT1;NSDHL;...
Th17 cell differentiation	-1.89	2.45e-2	95/107 (88.79%)	NFKBIA;ZAP70;HLA-DQB1;...
Mineral absorption	-1.95	2.21e-2	48/60 (80%)	ATP2B4;HMOX2;ATP1A2;...
Adipocytokine signaling pathway	-1.95	1.47e-2	64/69 (92.75%)	PRKAG2;ADIPOR1;NFKBIA;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	1.11uM - 10uM	24H	Hide ▲

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	1.11uM - 10uM	24H	Hide ▲